Navigation Links
EntreMed Announces Publication Of Preclinical Results For ENMD-2076 In Triple-negative Breast Cancer
Date:11/26/2012

selection, and may increase the probability of success. We are continuing to enroll patients in the ongoing Phase 2 trial and anticipate the initiation of a second site for this trial soon. We remain on track with our clinical development activities and expect our progress to accelerate in the coming months and year."

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company employing a drug development strategy primarily in the United States and China to develop targeted therapeutics for the global market.  Its lead compound, ENMD-2076, a selective angiogenic kinase inhibitor, has completed several Phase 1 studies in solid tumors, multiple myeloma, and leukemia, and is currently completing a multi-center Phase 2 study in ovarian cancer. EntreMed, Inc. recently initiated a Phase 2 study of ENMD-2076 in triple-negative breast cancer.  Additional information about EntreMed is available on the Company's website at www.entremed.com and in various filings with the Securities and Exchange Commission (the SEC).

About ENMD-2076

ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases which have been shown to play important roles in the pathology of several cancers. ENMD-2076 has shown promising activity in Phase 1 clinical trials in solid tumor cancers, leukemia, and multiple myeloma. ENMD-2076 is currently completing a Phase 2 trial for ovarian cancer.  EntreMed, Inc. recently initiated a Phase 2 study of ENMD-2076 in triple-negative breast cancer.

Forward Looking Statements   &#
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Dana-Farber Cancer Institutes Ursula A. Matulonis, MD Article on EntreMeds ENMD-2076 Published in the European Journal of Cancer
2. EntreMed Reports Second Quarter 2012 Financial Results
3. EntreMed Announces Initiation Of Phase 2 Trial In Triple-negative Breast Cancer
4. EntreMed Reports First Quarter 2012 Financial Results
5. Trovagene Announces Closing of Private Placement of $3.76 Million from the Sale of Restricted Common Stock and Warrants
6. ResMed Inc. Announces Exchange Rate For Upcoming Dividend Payment
7. AspenBio Pharma Announces Closing of Public Offering of 1,946,000 Shares of Common Stock
8. Vasomedical Announces Financial Results for the Third Quarter of 2012
9. Proteonomix, Inc. Announces Screening of Patients with End Stage Liver Disease in its Clinical Study of UMK-121
10. Ohr Pharmaceutical Announces Additions to Ophthalmic Scientific Advisory Board
11. NeuroDerm Announces Enrollment in a Phase 1 Study of ND0612, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 2013  BioElectronics Corporation (OTC Pink: BIEL), the maker ... the FDA panel meeting for non-thermal shortwave diathermy: ... Shortwave Therapy Meeting was held on May 21, 2013 ... focus of the meeting was very narrow, in that ... on the application of non-thermal shortwave diathermy for the ...
(Date:5/23/2013)... Conn. , May 23, 2013  CAS Medical Systems, ... medical devices for non-invasive patient monitoring, today announced that ... Officer,  will present at the 2 nd Annual Marcum ... Hyatt Hotel in New York City . ... p.m. ET in the Estate 10 room and will be ...
(Date:5/23/2013)... SAN DIEGO , May 23, 2013 /PRNewswire/ ... ) today announced the appointment of ... Officer.  Mr. Ramsay was most recently Vice President, ... http://photos.prnewswire.com/prnh/20100302/LA63139LOGO )     "With his established ... operational experience gained by working in our commercial ...
Breaking Medicine Technology:BioElectronics and Pulsed Shortwave Therapy Make Progress 2CASMED to Present at the 2nd Annual Marcum MicroCap Conference 2Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer 2
... Corporation (Nasdaq: SIAL ) will be presenting at ... 1:30 PM ET in New York, NY. Interested parties may ... http://investor.sigmaaldrich.com/ .  Users can click the "Webcast" icon to ... Sigma-Aldrich is a leading Life Science and High ...
... 23, 2011 ViewRay™, Inc., a privately held ... clearance for its radiotherapy treatment planning and delivery ... the company,s new radiation therapy system, which combines ... in the late stages of development, the integrated ...
Cached Medicine Technology:ViewRay Receives FDA 510(k) Marketing Clearance for Treatment Planning and Delivery Software 2
(Date:5/24/2013)... 24, 2013 Mike Stoler believes that ... successful business people in New York. That’s why ... weekly on CUNY TV. And that’s why he ... Allergy Associates, LLP (ENTA)—the largest single specialty practice in ... throat, allergy and audiology specialists and sub-specialists service communities ...
(Date:5/24/2013)... May 24, 2013 According to a May ... Social Media Leads to Spikes in Plastic Surgery ... a growing prevalence of facial plastic surgery and ... people have become keenly aware of the need to look ... as Facebook, Google and even Skype's video chat feature (Go ...
(Date:5/24/2013)... one in five parents think they have little control ... illicit drug use, a new U.S. government survey finds. ... Abuse and Mental Health Services Administration (SAMHSA), since new ... most influential forces helping to shape their child,s views ... show that parents can make an enormous difference in ...
(Date:5/24/2013)... aortic valve implantation (TAVI) is effective and safe in ... results from a multicentre Asian registry reported at EuroPCR ... a treatment option for selected patients with symptomatic severe ... North American or European centres," Paul Chiam, senior consultant ... conference. He explained that it is unknown whether the ...
(Date:5/24/2013)... Fit Yummy Mummy, a fitness program that ... trying to get rid of the belly fat in ... women who want to combine exercises with nutrition has ... Stevenson, prompting an investigative review. , “Holly's Rigsby's program ... variety of motivational strategies, nutritional plans, proper diets, and ...
Breaking Medicine News(10 mins):Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 2Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 3Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 4Health News:Facebook and Google – Is Social Media Driving Demand for Plastic Surgery? 2Health News:Parents Underestimate Influence Over Teens' Substance Abuse: Survey 2Health News:Registry confirms TAVI efficacy and safety in Asian patients 2Health News:Fit Yummy Mummy: Review Examining Holly Rigsby’s Fitness Program Released 2
... Washington, D.C., and Meet with Elected,Officials, WASHINGTON, March ... Washington, D.C., this April 1 to meet with,congressional leaders ... Disabilities Act, support for epilepsy public health,programs and more ... is one of 50 young people with epilepsy participating ...
... D.C., and Meet With Elected,Officials, WASHINGTON, March 14 ... D.C., this April 1 to meet with,congressional leaders and ... Act, support for epilepsy public health,programs and more research ... one of 50 young people with epilepsy participating in,Kids ...
... DENVER, March 14 Birner Dental Management,Services, Inc. ... dental practices,announced its regular quarterly dividend. The Company,s ... of 17 cents per share of common,stock. The ... of record,March 28, 2008., Birner Dental Management ...
... ( http://www.nhs.uk ), the,digital ,front door, to ... package on,pregnancy, aimed at helping people find ... Based on NHS accredited information, the pregnancy ... staying healthy and fit during pregnancy,including eating ...
... STE ) today announced that its Board ... $300 million in shares of STERIS common stock. ... of,February 29, 2008. This share repurchase authorization replaces ... Through March,13, 2008, the Company has repurchased approximately ...
... that processed vermiculite tainted with asbestos-like fibers that originated from ... and thickening of the membrane that lines the chest wall ... those who were exposed at or below current legal levels. ... times its original size when rapidly heated and has a ...
Cached Medicine News:Health News:Utah Youth Named National Epilepsy Spokesperson 2Health News:Tennessee Youth Named National Epilepsy Spokesperson 2Health News:STERIS Corporation Announces New $300 Million Share Repurchase Authorization 2Health News:STERIS Corporation Announces New $300 Million Share Repurchase Authorization 3Health News:Legal exposure to asbestos-like material linked to lung damage 25 years later 2Health News:Legal exposure to asbestos-like material linked to lung damage 25 years later 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: